Entyvio 300 MG vials
Ended Awarded Last action
- Contract number
- SPE2DR26FSCB2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $14,642
Award facts
- Contract value 100% obligated
- $14,642.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $14,642.04 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. The delivery order, issued on December 8, 2025, with an ultimate completion date of December 9, 2025, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion contract awarded on November 13, 2025, that establishes the company as a regional prime vendor contractor through December 31, 2036.
The PPV-G GEN V contract represents the Defense Logistics Agency's broader $30.3 billion pharmaceutical supply initiative designed to support Department of Defense healthcare operations globally through a tiered prime vendor structure. Under this framework, DMS Pharmaceutical Group is authorized to supply a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to military healthcare facilities worldwide. The current delivery order for Entyvio, a biologic immunosuppressant medication, exemplifies the company's role in fulfilling specialized pharmaceutical requirements across the federal military medical system, with the contractor demonstrating substantial performance capability across multiple therapeutic categories through numerous prior delivery orders issued by the Defense Logistics Agency.
Quick answers
Who was awarded contract SPE2DR26FSCB2?
SPE2DR26FSCB2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 8, 2025.
How much is contract SPE2DR26FSCB2 worth?
The government has obligated $14,642 on SPE2DR26FSCB2.
Is contract SPE2DR26FSCB2 an order under another contract?
Yes. SPE2DR26FSCB2 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSCB2 competed?
The extent of competition for SPE2DR26FSCB2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award